Trial Profile
A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease to Assess the Safety, Tolerability, pk, and Efficacy of Pepinemab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Pepinemab (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms SIGNAL; SIGNAL-HD
- Sponsors Vaccinex
- 26 Sep 2023 According to a Vaccinex media release, Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimers Disease Conference to be held in Boston on October 24-27, 2023.
- 01 Oct 2022 Results (n=265) published in the Nature Medicine
- 08 Aug 2022 Results published in the Vaccinex Media Release.